These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 12208739

  • 21. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR.
    Biochem Pharmacol; 2006 Jul 28; 72(3):293-307. PubMed ID: 16753135
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis.
    Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH, Evers BM.
    Surgery; 2001 Aug 28; 130(2):265-72. PubMed ID: 11490359
    [Abstract] [Full Text] [Related]

  • 24. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.
    LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS.
    Cancer Res; 2003 Jan 15; 63(2):468-75. PubMed ID: 12543804
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 27. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells.
    Kim YH, Park JW, Lee JY, Kwon TK.
    Carcinogenesis; 2004 Oct 15; 25(10):1813-20. PubMed ID: 15142888
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Perego P, Ciusani E, Gatti L, Carenini N, Corna E, Zunino F.
    Biochem Pharmacol; 2006 Mar 14; 71(6):791-8. PubMed ID: 16438941
    [Abstract] [Full Text] [Related]

  • 30. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ.
    Cancer Res; 2005 Jun 01; 65(11):4902-8. PubMed ID: 15930312
    [Abstract] [Full Text] [Related]

  • 31. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 32. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
    Van Geelen CM, de Vries EG, de Jong S.
    Drug Resist Updat; 2004 Dec 01; 7(6):345-58. PubMed ID: 15790545
    [Abstract] [Full Text] [Related]

  • 33. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N.
    Cancer Res; 2000 Aug 15; 60(16):4315-9. PubMed ID: 10969767
    [Abstract] [Full Text] [Related]

  • 34. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
    Nesterov A, Nikrad M, Johnson T, Kraft AS.
    Cancer Res; 2004 Jun 01; 64(11):3922-7. PubMed ID: 15173003
    [Abstract] [Full Text] [Related]

  • 35. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
    Ramaswamy M, Efimova EV, Martinez O, Mulherkar NU, Singh SP, Prabhakar BS.
    Oncogene; 2004 Aug 12; 23(36):6083-94. PubMed ID: 15208670
    [Abstract] [Full Text] [Related]

  • 36. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
    Kim DM, Koo SY, Jeon K, Kim MH, Lee J, Hong CY, Jeong S.
    Cancer Res; 2003 Feb 01; 63(3):621-6. PubMed ID: 12566305
    [Abstract] [Full Text] [Related]

  • 37. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
    Johnsen JI, Pettersen I, Ponthan F, Sveinbjørnsson B, Flaegstad T, Kogner P.
    Int J Oncol; 2004 Dec 01; 25(6):1849-57. PubMed ID: 15547726
    [Abstract] [Full Text] [Related]

  • 38. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L, Fang B.
    Cancer Gene Ther; 2005 Mar 01; 12(3):228-37. PubMed ID: 15550937
    [Abstract] [Full Text] [Related]

  • 39. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK, VanOosten RL, Griffith TS.
    Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266
    [Abstract] [Full Text] [Related]

  • 40. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.
    Cancer Res; 2005 Jun 01; 65(11):4799-808. PubMed ID: 15930300
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.